Literature DB >> 10637068

2-5A antisense directed against telomerase RNA produces apoptosis in ovarian cancer cells.

D M Kushner1, J M Paranjape, B Bandyopadhyay, H Cramer, D W Leaman, A W Kennedy, R H Silverman, J K Cowell.   

Abstract

OBJECTIVE: RNase L is converted to an active form upon binding short 2',5'-oligoadenylates (2-5A). To direct RNase L to an RNA target, 2-5A is attached to an antisense oligonucleotide (2-5A antisense). This chimera can be directed against telomerase-an RNA-protein complex that elongates telomeric DNA and is involved in cellular immortalization. Our objective is to investigate the effect of 2-5A antisense by targeting telomerase RNA (hTR) in the ovarian cancer cell line, HEY-1B.
METHODS: Baseline RNase L levels and telomerase activities were measured in both HEY-1B and normal ovarian epithelial cells (NOE). Cells were treated daily with chimeric oligonuclotides (ODN) directed against four different hTR sites, or control ODNs including nonchimeric antisense, 2-5A fused to a mismatched sequence, or inactive 2-5A fused to antisense. At 48 h, apoptosis was evaluated using the TUNEL assay. After six daily ODN administrations, telomerase activity was redetermined, and at 7 days viability counts were obtained.
RESULTS: Both cell lines expressed similar levels of RNase L. Hey-1B displayed telomerase activity while NOE did not. After 7 days of transfection, 2-5A antisense ODNs caused profound cell death in the HEY-1B cells, but not in the NOE cells. This effect was seen regardless of hTR target site, and ODN controls showed no significant decrease in cell viability in either cell line. HEY1B cells treated with 2-5A antisense against hTR showed a decrease in telomerase activity and a profound induction of programmed cell death.
CONCLUSIONS: The results suggest that 2-5A antisense directed against telomerase RNA results in apoptotic cell death in ovarian cancer cells, but not normal ovarian epithelial cells. The 2-5A antisense strategy may hold a considerable advantage over the conventional antisense approach in targeting cancer-causing genes. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10637068     DOI: 10.1006/gyno.1999.5668

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  12 in total

Review 1.  Natural and pharmacological regulation of telomerase.

Authors:  Jean-Louis Mergny; Jean-François Riou; Patrick Mailliet; Marie-Paule Teulade-Fichou; Eric Gilson
Journal:  Nucleic Acids Res       Date:  2002-02-15       Impact factor: 16.971

Review 2.  Tiptoeing to chromosome tips: facts, promises and perils of today's human telomere biology.

Authors:  J Fajkus; M Simícková; J Maláska
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2002-04-29       Impact factor: 6.237

3.  Effect of antisense oligodeoxynucleotide of telomerase RNA on telomerase activity and cell apoptosis in human colon cancer.

Authors:  Ying-An Jiang; He-Sheng Luo; Li-Fang Fan; Chong-Qing Jiang; Wei-Jin Chen
Journal:  World J Gastroenterol       Date:  2004-02-01       Impact factor: 5.742

Review 4.  Telomerase and the endocrine system.

Authors:  Furio Pacini; Silvia Cantara; Marco Capezzone; Stefania Marchisotta
Journal:  Nat Rev Endocrinol       Date:  2011-03-29       Impact factor: 43.330

5.  Indole-3-carbinol downregulation of telomerase gene expression requires the inhibition of estrogen receptor-alpha and Sp1 transcription factor interactions within the hTERT promoter and mediates the G1 cell cycle arrest of human breast cancer cells.

Authors:  Crystal N Marconett; Shyam N Sundar; Min Tseng; Antony S Tin; Kalvin Q Tran; Kelly M Mahuron; Leonard F Bjeldanes; Gary L Firestone
Journal:  Carcinogenesis       Date:  2011-06-21       Impact factor: 4.944

6.  Inhibition of human telomerase in MKN-45 cell line by antisense hTR expression vector induces cell apoptosis and growth arrest.

Authors:  Run-Hua Feng; Zheng-Gang Zhu; Jian-Fang Li; Bin-Ya Liu; Min Yan; Hao-Ran Yin; Yan-Zhen Lin
Journal:  World J Gastroenterol       Date:  2002-06       Impact factor: 5.742

7.  Antitumor mechanism of antisense cantide targeting human telomerase reverse transcriptase.

Authors:  Qing-You Du; Xiao-Bo Wang; Xue-Jun Chen; Wei Zheng; Sheng-Qi Wang
Journal:  World J Gastroenterol       Date:  2003-09       Impact factor: 5.742

8.  Antisense oligonucleotide targeting at the initiator of hTERT arrests growth of hepatoma cells.

Authors:  Su-Xia Liu; Wen-Sheng Sun; Ying-Lin Cao; Chun-Hong Ma; Li-Hui Han; Li-Ning Zhang; Zhen-Guang Wang; Fa-Liang Zhu
Journal:  World J Gastroenterol       Date:  2004-02-01       Impact factor: 5.742

9.  MYC drives overexpression of telomerase RNA (hTR/TERC) in prostate cancer.

Authors:  Javier A Baena-Del Valle; Qizhi Zheng; David M Esopi; Michael Rubenstein; Gretchen K Hubbard; Maria C Moncaliano; Andrew Hruszkewycz; Ajay Vaghasia; Srinivasan Yegnasubramanian; Sarah J Wheelan; Alan K Meeker; Christopher M Heaphy; Mindy K Graham; Angelo M De Marzo
Journal:  J Pathol       Date:  2017-11-14       Impact factor: 7.996

Review 10.  Telomerase and its potential for therapeutic intervention.

Authors:  P Phatak; A M Burger
Journal:  Br J Pharmacol       Date:  2007-07-02       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.